HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Donnie McGrath Selected Research

Atazanavir Sulfate (Reyataz)

4/2014Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
1/2014Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy.
10/2013Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
5/2012Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
11/2011Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
2/2011Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
6/2010Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
6/2009Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.
8/2008Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
2/2008Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Donnie McGrath Research Topics

Disease

4Jaundice (Icterus)
03/2013 - 08/2008
3Infections
04/2014 - 02/2008
3Hyperbilirubinemia
10/2013 - 05/2012
3Nausea
11/2011 - 08/2008
1Necrosis
01/2014
1Cardiovascular Diseases (Cardiovascular Disease)
01/2014
1Gilbert Disease
01/2014
1Neonatal Hyperbilirubinemia
10/2013
1Diarrhea
11/2011
1Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
06/2010
1Hyperlipidemias (Hyperlipidemia)
06/2009
1Drug-Related Side Effects and Adverse Reactions
07/2003

Drug/Important Bio-Agent (IBA)

10Atazanavir Sulfate (Reyataz)FDA Link
04/2014 - 02/2008
6Ritonavir (Norvir)FDA Link
04/2014 - 08/2008
5LopinavirFDA Link
04/2014 - 08/2008
4BilirubinIBA
01/2014 - 08/2008
2Tenofovir (Viread)FDA Link
04/2014 - 06/2010
2Emtricitabine (Emtriva)FDA Link
04/2014 - 06/2010
2RNA (Ribonucleic Acid)IBA
05/2012 - 06/2009
1Biomarkers (Surrogate Marker)IBA
01/2014
1C-Reactive ProteinIBA
01/2014
1Fibrinogen (Factor I)FDA Link
01/2014
1Interleukin-6 (Interleukin 6)IBA
01/2014
1Plasminogen Activators (Plasminogen Activator)IBA
01/2014
1RacivirIBA
05/2012
1Transaminases (Aminotransferases)IBA
05/2012
1EnzymesIBA
05/2012
1LDL CholesterolIBA
06/2009
1LipidsIBA
06/2009
1Protease Inhibitors (Protease Inhibitor)IBA
02/2008

Therapy/Procedure

1Therapeutics
07/2003